This database contains 30 studies, archived under the term: "tolerability"
Click here to filter this large number of results.
Medication adherence and tolerability of Alzheimer’s disease medications: study protocol for a randomized controlled trial
Campbell, Noll L.,
Dexter, Paul,
Perkins, Anthony J.,
Gao, Sujuan,
Li, Lang,
Skaar, Todd C.,
Frame, Amie,
Hendrie, Hugh C.,
Callahan, Chris M.,
Boustani, Malaz A.
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]
A randomized feasibility study of a 12-week community-based exercise program for people with Huntington’s disease
Busse, Monica,
Quinn, Lori,
Debono, Katy,
Jones, Karen,
Collett, Johnathan,
Playle, Rebecca,
Kelly, Mark,
Simpson, Sharon,
Backx, Karianne,
Wasley, David,
Dawes, Helen,
Rosser, Anne
BACKGROUND AND PURPOSE: The beneficial role of exercise as a treatment approach in Huntington’s disease (HD) has support from both preclinical work and small-scale studies; however, there have been no controlled studies of gym-based exercise in people with HD. This phase 2 randomized trial (ISRCTN 59910670) assessed feasibility, safety, acceptability, and benefit of a structured […]
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad, Bengt,
Andreasen, Niels,
Minthon, Lennart,
Floesser, Annette,
Imbert, Georges,
Dumortier, Thomas,
Maguire, R. Paul,
Blennow, Kaj,
Lundmark, Joens,
Staufenbiel, Matthias,
Orgogozo, Jean-Marc,
Graf, Ana
Background: Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer’s disease. We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer’s disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response.; Methods: We did a phase […]
Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study
Dubois, Bruno,
Tolosa, Eduardo,
Katzenschlager, Regina,
Emre, Murat,
Lees, Andrew J.,
Schumann, Günther,
Pourcher, Emmanuelle,
Gray, Julian,
Thomas, Gail,
Swartz, Jina,
Hsu, Timothy,
Moline, Margaret L.
Parkinson’s disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and […]
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin
Endres, Kristina,
Fahrenholz, Falk,
Lotz, Johannes,
Hiemke, Christoph,
Teipel, Stefan,
Lieb, Klaus,
Tüscher, Oliver,
Fellgiebel, Andreas
Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, München-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase-derived amyloid precursor protein (APPs-α).; Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg […]
Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial
Culo, Sandi,
Mulsant, Benoit H.,
Rosen, Jules,
Mazumdar, Sati,
Blakesley, Richard E.,
Houck, Patricia R.,
Pollock, Bruce G.
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]
An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration
Boxer, Adam L.,
Lipton, Anne M.,
Womack, Kyle,
Merrilees, Jennifer,
Neuhaus, John,
Pavlic, Danijela,
Gandhi, Anisha,
Red, Dana,
Martin-Cook, Kristen,
Svetlik, Doris,
Miller, Bruce L.
There are currently no Food and Drug Administration-approved treatments for frontotemporal lobar degeneration (FTLD). The objectives of this study were to explore the tolerability of memantine treatment in FTLD and to monitor for possible effects on behavior, cognition, and function. Forty-three individuals who met clinical criteria for FTLD [21 with frontotemporal dementia (FTD), 13 with […]